APA

Prins R. C., Burke R. T., Tyner J. W., Druker B. J., Loriaux M. M. & Spurgeon S. E. (20131210). CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. : Leukemia.

Chicago

Prins R C, Burke R T, Tyner J W, Druker B J, Loriaux M M and Spurgeon S E. 20131210. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. : Leukemia.

Harvard

Prins R. C., Burke R. T., Tyner J. W., Druker B. J., Loriaux M. M. and Spurgeon S. E. (20131210). CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. : Leukemia.

MLA

Prins R C, Burke R T, Tyner J W, Druker B J, Loriaux M M and Spurgeon S E. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. : Leukemia. 20131210.